CSIMarket Company Name, Ticker, Industry, else..
 
Sonnet Biotherapeutics Holdings Inc   (NASDAQ: SONN)
Other Ticker:  
 
 
Price: $1.5300 $0.01 0.658%
Day's High: $1.5807 Week Perf: -1.29 %
Day's Low: $ 1.46 30 Day Perf: -19.9 %
Volume (M): 59 52 Wk High: $ 18.72
Volume (M$): $ 90 52 Wk Avg: $8.88
Open: $1.53 52 Wk Low: $1.41



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Sonnet Biotherapeutics Holdings Inc
Sonnet Biotherapeutics Holdings Inc is a biotechnology company that specializes in developing innovative targeted immunotherapies for cancer treatments. The company focuses on utilizing its proprietary platform technology, called Immunopeptidomics, to create personalized medicines for patients with various types of cancer. Sonnet's approach involves identifying and targeting specific peptides expressed on cancer cells, leading to more effective and personalized treatments that can potentially enhance patient outcomes. The company's goal is to revolutionize cancer therapy by providing patients with highly personalized and targeted treatments that harness the power of the immune system to fight cancer.


   Company Address: 100 Overlook Center Princeton 8540 NJ
   Company Phone Number: 375-2227   Stock Exchange / Ticker: NASDAQ SONN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY      % 
CTMX   -14.43%    
NRIX   -4.66%    
SUPN   -4.66%    
WVE   -10.96%    
YMAB   -14.34%    
• View Complete Report
   



Contract

In the ongoing battle against one of the deadliest forms of cancer, pancreatic cancer remains a formidable ...

Published Mon, Aug 19 2024 12:45 PM UTC

Innovative Approaches to Pancreatic Cancer Treatment: Sonnet BioTherapeutics SON-1210 Clinical CollaborationIn the ongoing battle against one of the deadliest forms of cancer, pancreatic cancer remains a formidable challenge due to its late diagnosis and poor prognosis. Research teams and pharmaceutical companies are tirelessly seeking innovative solutions to improve treat...
Clinical Study

Positive Phase 1b Data Supports Advancement of SON-080 for Chemotherapy-Induced Peripheral Neuropathy

Published Wed, Jul 24 2024 12:30 PM UTC

In a recent announcement, Sonnet BioTherapeutics Holdings, Inc. revealed encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating SON-080 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). This milestone supports the further development of SON-080 into Phase 2, highlighting its potential as a targeted immunotherapeutic drug...
Stock Market Announcement

Sonnet BioTherapeutics Boosts Funds with $3.4 Million from Warrant Exercise

Published Thu, Jun 20 2024 12:31 PM UTC

Sonnet BioTherapeutics Raises $3.4 Million in Gross Proceeds through Exercise of Warrants
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has announced the exercise of certain outstanding warrants for the immediate purchase of 2,828,500 shares of common stock at a reduced price of $1.20 per share. This agreement is expected to result in gross proceeds of $3.4 million...
Clinical Study

Sonnet BioTherapeutics Strikes a Chord in Oncology: Unveiling SB221 at ASCO...

Published Tue, May 28 2024 12:00 PM UTC

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a company at the forefront of developing innovative targeted biologic drugs, has recently made a significant announcement. The company revealed that its ongoing SB221 study, evaluating the safety and efficacy of SON-1010 in combination with atezolizumab (Tecentriq?), will be showcased as a Trial in Progress poster at the ...
Sonnet Biotherapeutics Holdings Inc

Sonnet Biotherapeutics Holdings Inc. Reports Operating Loss of $-3.868561 Million in Second Quarter Financial Results 2.



Sonnet Biotherapeutics Holdings Inc, a company en route to establishing a solid business model in the biotech industry, released its financial results for the period spanning January to March 31, 2024. While the stockholders did not have high expectations regarding top-line changes, the company reported an operating loss during the same period, raising concerns. However, amidst these challenges, Sonnet Biotherapeutics showcased some positive developments, outperforming previous quarters and making progress towards its goals. Additionally, the company's stock performance has been underwhelming, facing significant dips in recent months.
Financial Results:
1. Operating Loss:
Sonnet Biotherapeutics recorded an operating loss of $-3.868561 million during the January to March 2024 reporting season. This unexpected loss has raised concerns among investors, who were anticipating a more stable financial performance. The reasons behind this operating loss should be further explored to understand the underlying issues affecting the company.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com